PCA(P)(2026)09 - Extension to SSP: Ramipril 1.25mg
Published: 8th July 2026
Purpose
This Circular advises Health Boards and community pharmacy contractors that the UK-wide Serious Shortage Protocol (SSP) for ramipril 1.25mg capsules remains in place following an extension to its expiry date.
The extension applies to SSP087 (ramipril 1.25mg capsules), which has been extended until Friday 24 July 2026. All other terms of the SSP remain unchanged. Under SSP087, community pharmacists may continue to restrict the total quantity supplied to one month's supply of the prescribed medicine.
Community pharmacists are advised to familiarise themselves with the revised end date for the above SSP.
Frequently Asked Questions (FAQs)
-
This SSP applies to ramipril 1.25mg capsules.
-
From 22nd April 2026 to 29th May 2026.
-
It allows pharmacists to restrict supply to one month’s quantity when prescriptions exceed one month.
-
No. It only allows restriction of quantity, not substitution to a different product.
-
Yes. It applies to both NHS and private prescriptions, including cross‑border prescriptions.
-
Details are published on the NHS Business Services Authority website and within SSP087.
This Circular advises Health Boards and community pharmacy contractors that the UK-wide Serious Shortage Protocol (SSP) for ramipril 1.25mg capsules remains in place following an extension to its expiry date.